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Short hairpin RNAs (shRNAs) capable of stably suppressing gene function by RNA interference (RNAi) can
mimic tumor-suppressor-gene loss in mice. By selecting for shRNAs capable of accelerating lymphomagen-
esis in a well-characterized mouse lymphoma model, we identified over ten candidate tumor suppressors,
including Sfrp1, Numb, Mek1, and Angiopoietin 2. Several components of the DNA damage response
machinery were also identified, including Rad17, which acts as a haploinsufficient tumor suppressor that
responds to oncogenic stress and whose loss is associated with poor prognosis in human patients. Our
results emphasize the utility of in vivo RNAi screens, identify and validate a diverse set of tumor suppressors,
and have therapeutic implications.INTRODUCTION
Tumor suppressors act in signaling networks that restrict cellular
proliferation and present barriers to malignant transformation.
For example, the p53 tumor-suppressor gene encodes a tran-
scription factor that can limit proliferation by promoting cell cycle
arrest, senescence, or apoptosis (Riley et al., 2008). p53 is
activated to inhibit proliferation in response to stress, including
replicative stress produced by mitogenic oncogenes, and thus
acts as part of a failsafe mechanism that halts the expansion of
aberrantly proliferating cells. Many other tumor suppressors,
each pointing toward programs or pathways that naturally limit
tumor growth, have been identified. Although generally not
considered direct drug targets, their loss of function can create
cellular dependencies that can be exploited therapeutically
(Vassilev et al., 2004).324 Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc.RNA interference facilitates loss-of-function genetics in
mammalian cells and has been used to explore various aspects
of cancer biology, including the function of tumor-suppressor
genes. Moreover, the availability of genome-wide libraries of
shRNAs capable of stably repressing gene expression has
enabled genetic screens for determinants of oncogenic transfor-
mation as well as potential therapeutic targets (Berns et al.,
2007; Westbrook et al., 2005). To study cancer phenotypes not
readily modeled in vitro, we have adapted RNAi technology to
suppress tumor-suppressor gene function in mice and have
used this technology to study aspects of tumorigenesis, tumor
maintenance, and treatment response (Hemann et al., 2003).
The Em-Myc lymphomamodel expresses the c-myc oncogene
in B cells (Adams et al., 1985) and has been used extensively for
identifying lesions that promote tumorigenesis, either through
retroviral-based insertional mutagenesis, by intercrossing withSIGNIFICANCE
Tumor-suppressor genes act in a variety of cellular processes to restrict oncogenic transformation, and their mode of action
can be context dependent. During tumorigenesis, genetic changes that circumvent these failsafe mechanisms are selected
for. By employing libraries of shRNAs in an in vivo RNAi screen in the Em-Myc model of B cell lymphoma, we speed up this
selective process and functionally identifymore than ten potential tumor-suppressor geneswhose suppression accelerates
lymphomagenesis. Our results illustrate how functional genetic approaches in mice complement genomic studies for iden-
tifying tumor-suppressor genes, andpoint toward newgenes and processes that influence cancer development. In addition,
they highlight the complexity of cancer gene action and suggest avenues for therapeutic intervention.
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In Vivo RNAi Screen for Lymphoma Suppressorsvarious transgenic or knockout mice or, more rapidly, by engraft-
ing Em-Myc-derived hematopoietic stem and progenitor cells
(HSPCs) transduced with a gene or shRNA into syngeneic recip-
ientmice (Schmitt andLowe, 2002).Using the latter approach,we
have shown that shRNAs targeting p53 or certain proapoptotic
genes can mimic the corresponding gene deletion by promoting
tumorigenesis (Hemann et al., 2003; Hemann et al., 2004). We
therefore reasoned that it should be possible to introduce
complex pools of shRNAs into Em-Myc progenitors, allowing for
the selection of those capable of promoting tumorigenesis in
transplanted recipients.
RESULTS
A p53 shRNA Can Be Recovered from Low-Complexity
Pools at High Efficiency
To identify appropriate conditions for an in vivo RNAi screen
using the Em-Myc model, we initially determined the complexity
of shRNAs that could be effectively screened in our HSPC trans-
duction/reconstitution assay using a shRNA targeting p53 as
a positive control. All shRNAs were based on the miR30 design,
where sequences homologous to the targeted gene are inserted
into a natural microRNA structure and thus are efficiently incor-
porated into the RNAi pathway and capable of potent knock-
down when integrated at single copy in the genome (Dickins
et al., 2005; Silva et al., 2005). The p53 shRNA (p53.1224) was
cloned into a retroviral vector that coexpressed green fluores-
cent protein (GFP), thereby enabling cells expressing shRNAs
to be tracked by flow cytometry or whole body fluorescence
imaging (Figure 1A).
As expected, Em-Myc HSPCs transduced with undiluted
p53.1224 typically produced tumors in recipient mice by 10
weeks, albeit with incomplete penetrance (Figure 1B). Similarly,
Em-Myc HSPCs transduced with 1:10–1:100 dilutions of
p53.1224 in empty vector or in a vector containing a control
shRNA produced tumors with a similar penetrance and slightly
longer latency. Tumors promoted by pools containing p53.1224
dilutions were invariably GFP positive (although only a subset of
the transplanted cells were infected), and sequence analysis
indicated that there was a strong selection for the p53 shRNA
relative to control vector. The tumors also displayed the B220+,
IgM immunophenotype and histopathology reminiscent of
lymphomas arising in Em-Myc transgenic animals (Figures 1C
and 1D; data not shown), implying that Myc was required for
tumorigenesis. Em-Myc HSPCs transduced with the empty retro-
viral vector or shRNAs targeting the human CCND1 or CDK5
genesdidnot produce tumors, and the few tumors that eventually
arose from negative controls were GFP negative (data not
shown). Therefore, tumor acceleration did not result from inser-
tional mutagenesis or a general perturbation of the RNAi
machinery but required a biologically active shRNA that could
be enriched from diluted pools.
The background frequency of Em-Myc lymphomas was less
than is observed for germline Em-Myc transgenic mice, which
typically develop lymphomas at complete penetrance between
15 and 30 weeks (Adams et al., 1985). This reduced penetrance
likely reflects the inability of Em-Myc HSPCs to provide long-term
reconstitution of the hematopoietic system of recipient mice
under the sublethal irradiation conditions used in our transplan-tation experiments. Indeed, we see that virally transduced cells
eventually were depleted from the peripheral blood of recipient
mice within 20 weeks (data not shown). We reasoned that
the low background of tumors arising in negative controls would
facilitate the identification of tumor-accelerating shRNAs by
creating a defined window in which a particular shRNA could
trigger malignant transformation. On the basis of these pilot
experiments, we designated 20 weeks posttransplantation as
the end point for our screen.
Figure 1. Strategy for an Efficient In Vivo RNAi Screen in the Em-Myc
Lymphoma Model
(A) Adoptive transfer strategy to develop chimeric mice stably expressing
GFP-tagged shRNAs in the hematopoietic system.
(B) Kaplan-Meier curve of overall survival in mice expressing dilutions of
p53.1224, vector alone, or control shRNA.
(C) Levels of GFP expression in peripheral blood and in lymphomas 3 weeks
after injection. Whole-body GFP imaging of a representative mouse shows
disseminated lymphoma in mice reconstituted with p53.1224.
(D) Hematoxylin-eosin, PCNA, and cleaved-caspase-3 staining of lymphomas
from mice reconstituted with 1:50 dilution of p53.1224. Scale bars represent
5 mm (C) and 100 mm (D).Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc. 325
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during Tumorigenesis
(A) The top-left panel shows the percentage of
GFP+ tumors in mice infected with vector (LMS)
(n = 10), control shRNA (n = 16), or p53.1224
(n = 30). Top-right and bottom panels show 27 of
48 shRNA pools produce GFP+ tumors in mice
(n = 3).
(B) Representative mice from a scoring pool
(A16EH) with GFP+ tumors inmultiple lymph nodes
(LN) and spleen (sp) (left) or from pools with no
advantageous shRNAs that do not give rise to
tumors (pool A14EH) (right).
(C) Percentage of sequencing reads of unique
shRNAs in pool A6EH prior to injection (left) and
in three independent tumors (right) that are mark-
edly enriched for shAng2 (Ang2.2112). Scale
bars represent 5 mm.In Vivo Screening Identifies Candidate shRNAs Capable
of Promoting Lymphomagenesis
Although the progenitor cell transplantation procedure described
above is scalable, it is not amenable to genome-wide shRNA
screening, which prompted us to seek out strategies to filter the
larger shRNA library into categories enriched for cancer relevant
genes. To start, we decided to survey shRNAs targeting the
‘‘cancer 1000’’ set of genes containing putative cancer-related
genes compiled from microarray expression data and literature
mining (Witt et al., 2006). The list contained potential tumor
suppressors, as well as oncogenes that were not predicted to
have an impact in our model and, in principle, would serve as
negative controls.
Approximately 2300 shRNAs targeting the mouse orthologs of
the cancer 1000 list were obtained from the CODEX RNAi library
(http://katahdin.cshl.edu:9331/RNAi_web/scripts/main2.pl) and
were transferred into the LMS vector in pools of 48. DNA
sequencing of a subset of pools confirmed that an appropriate
representation of shRNAs was retained. Although p53 shRNAs
promoted tumorigenesis at a 1:100 dilution (Figure 1B), we
reasoned that a large pool size in the range of 100 or greater
would increase the probability that high-potency shRNAs would
outcompete weaker shRNAs, and therefore chose a smaller pool
size of 48. Each pool was introduced into at least three indepen-
dent progenitor populations and was transplanted into irradiated
recipient mice, which were subsequently monitored for lym-
phoma formation by lymph node palpation and fluorescence
imaging. Positive (p53.1224) and negative controls (either empty
vector or a control shRNA) were included to rule out variations
between HSPC populations and behaved as expected from
our pilot studies (see Figure S1A available online).
Of the 48 pools tested, 27 produced GFP-positive lymphomas
in one, two, or three recipient mice (Figures 2A and 2B), suggest-
ing that they contained one or more tumor-promoting shRNAs.
To identify these shRNAs, we isolated genomic DNA from
lymphomas, amplified the integrated shRNAs using PCR, and
sequenced the amplified products. Most tumors showed enrich-
ment of a subset of the transduced shRNAs, typically containing
one to three shRNAs per tumor. As expected, the positive control
hairpin, p53.1224 in pool 9AD, was among the shRNAs that were
enriched (Table S1). An example of a scoring shRNA, is one that326 Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc.targets Angiopoietin2 (Ang2.2112), which was identified in
tumors obtained from three mice, and comprised more than
80% of sequence reads in one lymphoma (Figure 2C).
In Vivo Validation of Candidate Tumor Suppressors
Using Multiple shRNAs
From the analysis of the entire library, we identified >80 different
shRNAs that were present in tumors (Table S1). Because this
exceeded the number of genes we could feasibly validate
in vivo, we reasoned that the shRNAs that featured the highest
enrichment in tumors from the primary screen would be most
likely to validate when tested as individual shRNAs. We decided
to retest the first 15 of those identified that were highly enriched
(>80% of sequence reads from a single tumor), as well as
shRNAs that were identified as enriched in more than one inde-
pendent tumor. These shRNAs were reintroduced as individual
clones into Em-Myc progenitor cells and were assessed for their
ability to promote tumorigenesis in transplanted recipients. Ten
of fifteen shRNAs analyzed showed accelerated tumor onset in
at least a subset of animals (Table S2).
We also selected five shRNAs that were present in tumors but
were not highly enriched by the criteria described above. Of
these, only two promoted tumorigenesis when introduced as
individual shRNAs. One targeted the ataxia telangiectasia-
mutated (ATM) gene, whose loss is known to accelerate tumor-
igenesis in Em-Myc transgenic mice (Pusapati et al., 2006). The
other targeted Rad51C, which has been implicated in homolo-
gous recombination and the DNA damage response (Sharan
and Kuznetsov, 2007). By contrast, shRNAs targeting Max,
Edg5, and Fgf20 did not validate upon retesting, suggesting
that either not all shRNAs in the lymphomas were tumor
promoting or a cooperating shRNA from the pool was required.
We also retested six shRNAs from the library that were not
observed in tumors or fell far belowour cutoff for follow-upvalida-
tion (Table S2). As expected, none of these shRNAs validated
in vivo. Therefore, although our screen probably did not uncover
all tumor-promoting shRNAs contained in our library, many of the
enriched shRNAs target genes that have properties of tumor
suppressors. Still, that each shRNA (including our positive
control) produced tumorswith incomplete penetrancesuggested
that the combination of Myc and each shRNA was not sufficient
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In Vivo RNAi Screen for Lymphoma Suppressorsfor lymphomagenesis, but that additional lesions were required.
Although insertional mutagenesis might supply some coopera-
tive events, it is probably not sufficient because (1) our negative
controls never showed tumor acceleration within the given time
period (Figure 2A; see also Figure 3A), and (2) many pools and
shRNAs tested in an identical manner were not tumor promoting.
Genes silenced by five of the validated shRNAs were chosen
for further investigation because they targeted potentially impor-
tant pathways in cancer development. Specifically, Mitogen
Activated Protein Kinase Kinase 1 (MEK1) is a component of
the MAPK pathway; Angiopoietin2 (Ang2) is a regulator of angio-
genesis; Secreted Frizzled-Related Protein 1 (Sfrp1) and Numb
are negative regulators of the Wnt and Notch pathways, respec-
tively; and Rad17 is involved in the DNA damage response.
Tumors that arose from shRNAs against these genes were
confirmed by RT-QPCR to have reduced expression of the tar-
geted gene (Figure S1B).
Figure 3. Validation of Tumor-Suppressor
Gene Activity In Vivo
(A) Kaplan-Meier curves of overall survival in mice
with shRNAs for candidate genes as indicated. At
least three individual shRNAs against each of the
five candidate genes as well as a small pool of
DNA damage response genes (two to three
shRNAs/gene; prkdc, atm, and rad51c) were
tested in at least five mice. The overall survival
difference between the shRNAs Rad17.1169/232
and Rad17.2159/2567 was statistically significant
(p < 0.01).
(B) shRNA competition assay in Arf//Em-Myc
lymphoma cells. Cells were infected with the indi-
cated shRNAs coupled to GFP, and the fraction of
GFP+ cells shown as bar graphs ± SEMwas moni-
tored over time by flow cytometric measurement
every other day over 14 days. A representative
experiment of three independent assays run in
duplicate is shown.
Several independent shRNAs targeting
each of these genes were generated and
introduced into our HSPC transplantation
assay (Figure 3A). In all cases examined,
multiple shRNAs targeting each gene
accelerated tumorigenesis in at least
a subset of recipient mice, thereby ruling
out off-target effects of individual
shRNAs. Immunophenotyping revealed
that all lymphomas were of pre-B cell
origin (B220+, IgM), suggesting that
most tumor-promoting shRNA acted
directly on tumorigenesis rather than
modulating the cell of origin of the
disease (Figure S3). Interestingly, when
introduced into Myc-overexpressing ARF
null lymphomas in vitro, shRNAs target-
ing p53, Rad17, and to a lesser extent
Mek1 enhanced proliferation in a compe-
tition assay (Figure 3B). In contrast, those
targeting Ang2, Sfrp1, and Numb did not
confer any competitive advantage, implying that the tumor-
promoting effect of repressing these genes depends on the
in vivo microenvironment or pathways spontaneously altered
during lymphomagenesis, underscoring the value of an in vivo
screen.
Mek1 Can Have Tumor-Suppressive Properties
In validating our findings, we were surprised that some of the
genes we identified as tumor suppressors have pro-oncogenic
properties in other contexts. Thus, although angiopoietin 2 was
identified as an antiangiogenic protein (Maisonpierre et al.,
1997), it can also be proangiogenic in vivo (Lobov et al., 2002).
Likewise, Mek1 can transmit oncogenic signals downstream of
ras (de Vries-Smits et al., 1992) but is also required for the trans-
mission of checkpoint signals in response to both oncogenic and
genotoxic stress (Lin et al., 1998; Zhu et al., 1998; Yan et al.,
2007). As expected, tumors triggered by Mek1 shRNAsCancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc. 327
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level of phospho-ERK1/2, two downstream targets (Figure 4A).
Interestingly, acute activation of Myc triggered the phosphoryla-
tion of the Mek targets Erk1/2 in a Mek-dependent manner (Fig-
ure 4B), and treatment of cells with a Mek1 inhibitor attenuated
Myc-induced cleavage of the apoptosis effector PARP, as well
as activation of p53 and the DNA damage response proteins
RAD17 and gH2AX (see below) (Figures 4C and 4D). Further-
more, primary B cells coexpressing Myc and a Mek1 shRNA
were selected for in an in vitro competition assay, whereas cells
expressing the Mek1 shRNA alone depleted over time (Figures
4E and 4F). Together, these data imply that Mek1 is a context-
dependent tumor suppressor whose antiproliferative action is re-
vealed in Myc-expressing cells.
RAD17 Is Activated by Myc
The DNA damage response (DDR) promotes checkpoint activa-
tion after DNA damage, including that produced by exogenous
DNA damaging agents or after replication stress (Halazonetis
et al., 2008). Consistent with a crucial role of these checkpoints
in limiting malignant transformation, a substantial number of our
validated shRNAs target DDR genes. Among these were Rad17,
Figure 4. Mek1 Can Have Tumor-Suppres-
sive Properties
(A) Extracts from tumor cells derived from mice
transplanted with Em-Myc HSPC expressing either
p53.1224 or Mek1.1200 shRNAs were immuno-
blotted for Mek1, phospho-Erk1/2, and tubulin.
(B) IMR90 cells stably expressing MycER were
starved in serum-free medium for 16 hr; this is fol-
lowed by MycER induction with 4-OH-tamoxifen
(TMX) for the indicated lengths of time in either
the presence or absence of 20 mM PD98059
(Mek1 inhibitor). Immunoblots of cell extracts
were probed for phosho-Erk1/2 and tubulin.
(C) Wild-type IMR90 cells or IMR90 cells stably
expressing MycER were induced with TMX for the
indicated lengths of time in either the presence or
absence of PD98059. Immunoblots of cell extracts
were probed for cleaved-PARP, Rad17, phospho-
Rad17, p53, phospho-p53, gH2AX, and tubulin.
(D) Early passage wild-type MEF were infected
with either Myc or empty vector and grown for
48 hr after infection in the presence of PD98059.
Immunoblots of cell extracts were probed for
cleaved-PARP, phospho-Rad17, p53, phospho-
p53, and tubulin.
(E and F) Wild-type or Em-Myc mouse B cells were
infected with shRNAs targeting either p53
(p53.1224) or Mek1 (Mek1.1200) both linked to
a GFP reporter. The fraction of GFP+ cells was
monitored over time by flow cytometric measure-
ment at the intervals indicated. Experiments were
performed three times with six replicates. Error
bars reflect SEM.
ATM, Rad51C, and Prkdc (DNA PK cata-
lytic subunit)—all of which were validated
as tumor suppressors in vivo (Figure 3A).
Previous studies suggest that Atm and
Prkdc can have tumor-suppressive
effects in the hematopoietic system, and loss of rad51C can
promote tumorigenesis in mice (Xu et al., 1996; Jhappan et al.,
1997; Kuznetsov et al., 2009). However, despite its central role
in the DNA damage response, the contribution of Rad17 to
cancer development has not been examined.
Rad17 acts as part of a complex that assembles the DNA-
damage repair sliding clamp onto DNA at sites of damage and,
in fission yeast, is required for both the DNA damage and the
DNA replication cell cycle checkpoints (Parker et al., 1998).
Rad17 activity is positively regulated by ATR through phosphor-
ylation at serines 635/645 and facilitates phosphorylation of
Chk1 by ATR in response to replication stress and DNA damage
to maintain genomic stability (Wang et al., 2006; Wang et al.,
2003; Bao et al., 2001). Four different shRNAs targeting Rad17
consistently promoted lymphomagenesis, albeit with different
latencies and variable penetrance (Figure 3A). As expected,
the resulting tumors showed knockdown of Rad17 (Figure 5A).
Although DDR pathways may indirectly limit tumorigenesis by
maintaining genomic stability, they may act more directly by
mediating antiproliferative responses to cellular stress. Indeed,
ectopic activation of the myc oncogene, which serves as the
primary genetic lesion in our screen, triggers a replication328 Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc.
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Checkpoint Protein Rad17 Is Phosphory-
lated after Myc Induction, and shRNA-Medi-
ated Knockdown of Rad17 Attenuates
Effects of Myc-Induced Stress Responses
(A) Immunoblot of tumor samples from animals
transplanted with HSPC expressing Rad17
shRNAs or p53.1224 shRNA controls probed for
phospho-Rad17 (Ser645) and total Rad17 protein.
b-actin was used as a loading control.
(B) Lymphocytes from three wild-type (WT) mouse
spleens and lymphoma cells derived from three
Em-Myc transgenic animals were analyzed for
phospho-Rad17 (Ser645), c-Myc, and Tubulin
expression by immunoblotting.
(C) In the top panel, the effect of acute Myc activa-
tion on Rad17 was studied by infecting early
passage murine embryonic fibroblasts (MEF) cells
with an inducible MycER construct, harvesting
cells after Myc induction with TMX at the indicated
time points, and immunoblotting for phospho-
Rad17 expression. b-actin was used as a loading
control. In the lower panel, a similar analysis was
performed to examine the effects of acute Ras
activation on Rad17 and Erk1/2 phosphorylation
by infecting human IMR90 cells with a RasER
construct and harvesting cells after Ras induction
with TMX at the indicated time points for immuno-
blotting. Tubulin was used as a loading control.
(D) Human IMR90 fibroblast cells were infected
with a MycER construct and analyzed for protein
expression of Rad17, phospho-Rad17 (Ser645),
p53, phospho-p53 (Ser15), gH2AX, and Tubulin
either untreated or 24 hr after TMX addition.
(E) MEF cells infected with Myc and/or Rad17.
1169 shRNA were analyzed for phospho-Rad17,
p53, p19, cleaved PARP, and tubulin expression
by immunoblotting as indicated.
(F) Colony formation was analyzed by plating
MEFs infected with the indicated constructs at
low density and counting colony numbers after
10 days. Results from four independent experi-
ments are shown.
(G) Cell death induction in MEFs infected with vector control, a p53 shRNA (p53.1224), a Rad17 shRNA (Rad17.1169) alone, and in combination with a Myc cDNA
was determined 48 hr after infection by flow cytometry following propidium iodine staining. Results from four independent experiments are shown.
(H) BrdU incorporation was measured in MEFs coinfected with MycER and either a control (CDK5) or a Rad17.1169 shRNA. In three independent experiments,
cells were pulse-labeled with BrdU 48 hr after Myc induction and harvested, and BrdU incorporation was determined in untreated or Myc-induced cells by flow
cytometry. All bar graphs are shown ± SEM.stress-induced DNA damage response leading to delayed S
phase progression and/or apoptosis (Karlsson et al., 2003;
Dominguez-Sola et al., 2007). Accordingly,we found that Em-Myc
lymphomas expressed much more phosphorylated, hence
activated,Rad17 thandidcontrol lymphocytes in vivo (Figure 5B).
Furthermore, enforced Myc expression rapidly triggered Rad17
and Chk1 phosphorylation in a manner that paralleled its ability
to induce ARF and p53 (Figures 5C, top, 5D, and 5E; Figure S4).
Of note, oncogenic Ras expression also triggered RAD17 phos-
phorylation in normal diploid fibroblasts (Figure 5C, bottom), indi-
cating that other mitogenic oncogenes can activate RAD17.
Interestingly, the Rad17 shRNAs that were most effective at
promoting lymphomagenesis (Rad17.1169 and Rad17.232)
also most prominently attenuated antiproliferative responses to
Myc. Hence, cells coexpressing Myc and Rad17.1169 displayed
reduced phospho-p53 and p19ARF levels (Figure 5E), suggest-ing attenuation of these oncogene-induced failsafe programs.
More importantly, these Rad17 shRNAs enhanced colony forma-
tion in Myc-expressing MEFs, which also displayed reduced
apoptosis and enhanced proliferation (Figures 5F–5H). Consis-
tent with the possibility that Rad17 is required for the response
to oncogene-induced replicative stress, the selective advantage
produced by Rad17 suppression was more pronounced in
primary B cells expressing Myc compared with normal controls
(Figure S2A). Intriguingly, the attenuation of this replication stress
checkpoint also appears to be an indirect outcome of Mek1 inhi-
bition (see Figures 4C and 4D), suggesting its central role in
tumor suppression.
Rad17 Is a Haploinsufficient Tumor Suppressor
Although we confirmed the above results by using multi-
ple Rad17 shRNAs, we noted dramatic shRNA-dependentCancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc. 329
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Tumor Suppressor
(A) In vitro competition assay with different Rad17
shRNAs in Em-Myc/Arf/ lymphoma cells. Cells
were infectedwith the indicated shRNA constructs
coupled to EGFP and monitored by daily flow
cytometric measurements of EGFP+ cells over
16 days. The bar graph shows a representative
experiment of at least three assays run in
duplicate ± SEM.
(B) Immunoblot analysis of Rad17 knockdown by
the indicated shRNAs inMEF cells. The upper panel
shows a representative blot, and the lower bar
graphshowsthequantificationof threeexperiments
normalized to tubulin as loading control ± SEM.
(C) Flow cytometric analysis of peripheral blood
(PB) leukocytes in representative mice trans-
planted with the indicated shRNAs 4 weeks after
transplantation. Erythrocytes were removed by
osmotic lysis, and cells were analyzed after stain-
ing with a B cell-specific antibody (B220).
(D) Dynamics of EGFP+/B220+ cells representing
shRNA-infected B cells in the PB over the first
30 days after transplantation. Percentages of all
EGFP+ cells at the time of transplant and of the
EGFP+/B220+ population at 30 days are shown for
5micepergroup infectedwith the indicatedshRNAs.
(E) Immunofluorescence staining of gH2AX
expression in MEFs infected in duplicate with
control, Rad17.1169, and Rad17.2159 shRNAs.
Cells were fixed and stained 48 hr after infection
and selection. As positive control, part of the
control-vector-infected cells were treated with
adriamycin (ADR). Scale bars represent 20 mm.
(F) Quantification of the gH2AX analysis shown in
Figure 6E. Bars represent percent gH2AX+ cells ±
SD. Cells containing more than three gH2AX foci
were counted as positive. At least 250 cells per
duplicate infectionwereevaluated for eachshRNA.
(G) Cell cycle analysis of 3T3 murine fibroblast cells infected with the indicated shRNAs and arrested in G2 phase by treatment with 200 ng/ml nocodazole for
48 hr. In three independent experiments, the cells were fixed, stained with propidium iodide, and analyzed for cell cycle distribution by flow cytometry. The >4N
fraction was determined after gating out cell doublets (see Experimental Procedures). Error bars reflect SEM.differences in colony formation assays. For example, some
Rad17 shRNAs (Rad17.1169 and Rad17.232) enhanced colony
formation, whereas others (Rad17.2567 and Rad17.2159) had
the opposite effect (Figure S2B). Accordingly, in a competition
assay using Em-Myc-ARF/ lymphoma cells, those shRNAs
that decreased proliferation were selected against, whereas,
as shown above, those that enhanced proliferation were en-
riched (Figure 6A). Although, in principle, these differences might
reflect off-target effects of RNAi, at least two independent
shRNAs targeting Rad17 were able to confer a proliferative
advantage or disadvantage, respectively, and all were tumor
promoting to at least some degree (see Figure 3A).
Immunoblotting of cell lysates in this setting of acute Rad17
knockdown revealed an inverse correlation between Rad17
protein levels and proliferative advantage, with shRNAs that
intrinsically produced the most potent knockdown being more
strongly selected against (Figures 6A and 6B). Furthermore,
those Rad17 shRNAs that conferred a proliferative advantage
initially showed only modest Rad17 suppression, although
Rad17 levels decreased upon further propagation (data not
shown). Presumably, these polyclonal populations contained330 Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc.cells harboring a discreet range of Rad17 levels such that those
with optimal knockdown eventually dominated the population.
Consistent with these in vitro results, analysis of peripheral blood
frommice reconstitutedwith Em-MycHSPCs showed that B cells
harboring weak RAD17 shRNAs were more rapidly enriched
in vivo than those harboring potent Rad17 shRNAs (Figures 6C
and 6D). These observations apparently explain the inverse
correlation between the ability of Rad17 shRNAs to suppress
Rad17 expression and promote tumorigenesis, with the most
potent shRNAs being the least oncogenic (Figure 3A). In
contrast, the potency of each Rad17 shRNAwas directly propor-
tional to their ability to attenuate Chk1 phosphorylation in
response to exogenous DNA damaging agents or activation of
Myc (Figure S4), implicating Chk1 as one downstream effector
for the observed effects. Presumably, suppression of Rad17
beyond a crucial threshold is deleterious to proliferation.
The above results are consistent with observations that Rad17
null and Chk1 knockout mice die during embryogenesis
(Budzowska et al., 2004; Liu et al., 2000) and that deletion of
Rad17 in certain tumor lines leads to endoreduplication,
chromosomal aberrations, and apoptosis (Wang et al., 2003).
Cancer Cell
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cell Lymphoma, and Its Status Impacts the Survival
of Lymphoma Patients
(A) Rad17 mRNA expression in normal human B cells,
compared with that in B cell lymphoma samples. The
graphs were derived from published data available
through the ONCOMINE database (Alizadeh et al., 2000).
(B) Prognostic impact of Rad17 expression on the overall
survival (OS) of B cell lymphoma patients. Patients were
grouped in either high or low Rad17 expressors according
to their individual Rad17 levels, compared to the mean
Rad17 mRNA expression of the total population. OS was
determined by Kaplan-Meier analysis, and statistical
difference was determined by log-rank test. Rad17
mRNA expression and patient survival data were obtained
from a previous study on patients with Burkitt- and diffuse-
large-cell B-lymphoma (Hummel et al., 2006).
(C) The human Burkitt lymphoma lines Raji, Daudi, and
Bjab were analyzed in duplicate for Rad17 protein expres-
sion by immunoblotting.
(D) Rad17 re-expression in Bjab lymphoma cells. In a GFP
competition assay, cells were infected with a MSCV-
Rad17-IRES-EGFP construct coexpressing the Rad17
cDNA and EGFP. The percentage of EGFP+ cells was
determined daily by flow cytometry analysis in three inde-
pendent experiments run in duplicate. Error bars reflect
SEM.
(E) Average deletion counts per tumor in ROMA profiles
from 298 patients with breast cancer (left panels) and
134 patients with colon cancer (right panels) plotted
against chromosomal position. Copy-number profiles underwent normalization, segmentation, and masking of frequent copy number polymorphisms (Hicks
et al., 2006). Average deletion frequencies for Rad17 and other relevant tumor-suppressor genes as well as a magnification of the Rad17 chromosomal region
are shown for both tumor types.Accordingly, the most potent Rad17 shRNAs (Rad17 shRNAs
2567 and 2159) triggered a DNA damage response as assessed
by their ability to promote more phospho-H2AX (gH2AX) foci in
MEFs relative to controls and the less potent Rad17 shRNAs
(1169 and 232) (Figures 6E and 6F). Moreover, as described for
Rad17-deficient cells, nocodazole treatment of cells expressing
the most potent Rad17 shRNAs (but not those with weaker
suppressive activity) showed less G2/M accumulation and
increased polyploidy, compared with controls (Figure 6G).
Together, these results suggest that partial suppression of
Rad17 confers a proliferative advantage by enabling cells to
evade an oncogene-induced replicative stress response,
whereas further suppression of Rad17 is deleterious to prolifer-
ation owing to catastrophic failure in DNA repair and excessive
genomic instability. As such, Rad17 has properties of a haploin-
sufficient tumor suppressor.
RAD17 and Human Cancer
The identification of shRNAs targeting p53 and ATM—genes
affected by loss-of-function mutations in human tumors—high-
lights the potential of this in vivo RNAi screen to identify clinically
relevant tumor-suppressor genes. Available literature on hits
from our screen further supports this notion: in human tumors,
the promoter of SFRP1 is found methylated, and NUMB has
been attributed tumor-suppressor functions and is found under-
expressed in breast cancer (Pece et al., 2004; Stylianou et al.,
2006). By surveying public gene expression databases (http://
www.oncomine.org), we found that RAD17 was significantlyunderexpressed in a substantial fraction of human diffuse large
B cell lymphomas (Figure 7A), which correlated with poor prog-
nosis (Figure 7B). Consistent with the data from primary human
lymphomas, several human lymphoma lines displayed varying
degrees of RAD17 expression (Figure 7C).
To further validate the function of RAD17 as a tumor sup-
pressor, we re-expressed its cDNA coupled to a GFP-reporter
in Bjab humanBurkitt lymphoma cells (featuring the lowest levels
of RAD17) and performed cell competition assays. As expected,
cells expressing exogenous RAD17 were outcompeted,
compared with controls (Figure 7D). Similarly, forced RAD17
expression has been shown to slow tumor growth in nude
mice (Beretta et al., 2008). Of note, a nonphosphorylatable
(S635A/S645A) mutant Rad17 was still selected against, albeit
to a lesser degree than wild-type Rad17, suggesting that its
tumor-suppressive properties are partially independent of phos-
phorylation at these residues (data not shown). Together, these
data support a role of Rad17 as a tumor suppressor in both
murine and human cells.
By surveying a database of copy number alterations at Cold
Spring Harbor Laboratory, we noted that RAD17 is frequently
deleted in breast and colon cancer (Figure 7E), where its under-
expression is common; in breast cancer, it correlates with poor
prognosis (http://www.oncomine.org). Similarly, previous
studies have suggested that RAD17 can be deleted in head
and neck cancer (Zhao et al., 2008). Although deletions encom-
passing RAD17 are often large and may include other tumor-
suppressor genes, their frequency in breast and colon cancerCancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc. 331
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as PTEN (Figure 7E). Together with our functional studies, which
demonstrate that RAD17 acts is a haploinsufficient tumor
suppressor in mice, these observations suggest that RAD17
has tumor-suppressor activity in humans and heterozygous
loss may promote tumorigenesis.
DISCUSSION
Here, we identified tumor-suppressor genes targeting an array of
biological processes by conducting a forward genetic screen
using a biologically relevant end point—tumorigenesis. Although
further studies will explore how each gene acts to suppress
tumorigenesis, several have biological activities not readily as-
sayed in vitro. Notably, our screen was not exhaustive: improve-
ments in shRNAknockdownefficiency, a broader screen, a larger
cohort of animals, and/or expansion to other tumor models will
undoubtedly yield additional relevant genes. Hence, this study,
when placed in the context of other studies to functionally iden-
tify cancer genes, implies that there are a surprisingly large
number of genes that, when deregulated in an appropriate
genetic background, can contribute to malignancy.
Our approach conceptually parallels the replication compe-
tent retrovirus-based insertional mutagenesis screens that
have identified candidate oncogenes in the Em-Myc model and
other systems (Uren et al., 2005). However, none of our top-15
candidate tumor suppressorswere identified as sites of common
insertions in Em-Myc or other lymphoid-based insertional muta-
genesis screens (Akagi et al., 2004), suggesting that shRNA
screening interrogates a distinct set of genes. Our shRNA-based
approach allows a defined selection of genes to be screened,
and, owing to the trans-acting effects of RNAi, one integration
is, in principle, sufficient to inactivate gene expression from
two alleles. Thus, our approach complements insertional muta-
genesis screens and identifies yet additional uses for the well-
characterized Em-Myc mouse model.
In parallel to the current study, we also conducted an RNAi
screen using a mouse model of hepatocellular carcinoma
(Zender et al., 2008). In this setting, we chose shRNAs targeting
the mouse orthologs of genes deleted in human HCC as a guide
to enrich the RNAi library for tumor-suppressor genes. By
expanding to a different in vivomodel in this study and employing
a more broadly defined set of shRNAs, we discovered tumor-
suppressor genes that would not have been identified on the
basis of genomics data alone. Interestingly, preliminary
screening of theCancer1000 library in theHCCmodel uncovered
candidate tumor suppressors not identified in the lymphoma
screen, whereas several hits from the lymphoma screen did not
accelerate liver tumorigenesis (L.Z., W. Xue, and S.W.L., unpub-
lished data). These observations indicate that many tumor-
suppressor genes function in a context-dependent manner and
highlight the value of conducting shRNA-based screens in
multiple tumor models.
We chose to investigate in detail one of our candidate tumor-
suppressor genes, rad17. Together, our data support a model
wherein Rad17 acts as a haploinsufficient tumor suppressor by
mediating replication stress from oncogenes to both p53-depen-
dent and independent antiproliferative responses. Alleviation
of this effect allows proliferation to continue inappropriately. Of332 Cancer Cell 16, 324–335, October 6, 2009 ª2009 Elsevier Inc.note, lymphomas triggered by the most oncogenic Rad17.
1169 shRNA retained a wild-type p53 gene and intact p53
response, suggesting that p53-loss is not required for Rad17
suppression to promote tumorigenesis (data not shown). There-
fore, although attenuation of Rad17 activity may eventually lead
to genomic instability and contribute indirectly to tumorigenesis,
we believe that the more direct effect on the cell cycle described
here is likely to explain its action as a tumor suppressor in our
system. In line with previous studies, we found Chk1 activation
to be Rad17 dependent. Interestingly, Chk1 also displays phe-
notypes consistent with a haploinsufficient tumor suppressor—
namely, deregulated cell cycle entry—accelerated tumor devel-
opment and, if homozygously deleted, embryonic lethality due to
excessive DNA damage (Liu et al., 2000; Lam et al., 2004)
The identification of Rad17 as a tumor suppressor demon-
strates the potential of shRNA-based screens to discover and
validate haploinsufficient tumor suppressors whose partial loss
of expression is pro-oncogenic, but whose complete loss of
function is deleterious for preneoplastic cells (Payne and
Kemp, 2005). On the basis of the variable potencies of different
shRNAs that target the same gene, in vivo RNAi screens are able
to survey a broad dynamic range of target gene expression for
which those cells with optimal knockdown will be selected for
during tumorigenesis. In support of this concept, Rad17 shRNAs
that induce distinct levels of knockdown after acute introduction
into cell populations feature a more homogeneous suppression
of Rad17 in the outgrown tumors (compare Figure 5A with
Figure 6B).
Importantly, genomic deletions found in human tumor
samples are often hemizygous, and it is often assumed that rele-
vant tumor suppressors must display concomitant loss or
suppression of the remaining wild-type allele. Indeed, reduced
expression of Rad17 is observed in human diffuse large B cell
lymphoma (DLBCL), and this correlates with poor prognosis.
Although it remains to be determined whether hemizygous dele-
tions involving Rad17 occur in DLBCL, they occur and are
common in human colon and breast cancer. As such, hemizy-
gous deletions in cancer cells can be quite large, and there
may be many other genes that can contribute to cancer when
reduced to a single copy. Because, in these instances, there is
no clear mutation in a second allele, it is difficult to determine
their relevance though genomic approaches alone.
We were surprised that some genes with putative oncogenic
properties were identified in our screen, implying that many
genes can act as either pro- or antioncogenic, depending on
genetic or cellular context. As an example, Mek1, a critical
effector in the MAPK pathway, scored in all our assays. Although
seemingly paradoxical, these studies are consistent with
previous work showing that Mek is required for DNA checkpoint
activation in response to genotoxic stress (Yan et al., 2007). Anti-
proliferative functions of Mek have furthermore been corrobo-
rated by studies demonstrating that high-dose MAPK signaling
can produce antiproliferative responses (Olson et al., 1998) and
by studies suggesting that, in premalignant cells, Mek is required
for Ras-induced senescence—a tumor-suppressive program
(Lin et al., 1998; Zhu et al., 1998). In addition, Mek1 inhibition
may destabilize Myc (Sears et al., 2000), enabling proliferation
without apoptosis (Murphy et al., 2008), or interfere with a feed-
back mechanism that would otherwise dampen proliferation
Cancer Cell
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Mek1 suppression accelerates tumorigenesis, our data, together
with published reports, emphasize that the physiological
response to Mek1 inhibition is highly context dependent and
strongly influenced by the genetic background in which it occurs.
Although our goal was to identify genes that limit tumorigen-
esis, our results have therapeutic implications. First, because
many chemotherapeutic agents trigger a DNA damage response
whose integrity can influence treatment outcome, knowledge of
RAD17 status in tumorsmay help guide the use of chemotherapy
in patients. Second, owing to their pro-oncogenic activities in
certain settings, some of the tumor suppressors we identified
(e.g., MEK1 and ANG2) are targets of inhibitors in clinical trials
(Rinehart et al., 2004); our observations hint that contextual infor-
mation may be required for the effective use of these inhibitors in
the clinic. Finally, our screen identified several tumor-suppressor
genes that encode secreted proteins, including Sfrp1, Ang2,
Fgf15, Wnt1, Shbg, and Bmp3 (Table S2; see also Zender
et al., 2008). Because shRNAs targeting these genes were
isolated from pools of cells in which only a portion contain
a particular shRNA, it is likely that these factors operate either
in an autocrine manner, or as short-range paracrine signals
that alter the microenvironment in ways that stimulate tumori-
genesis. Still, if loss of these proteins is required to sustain tumor
progression, systemic delivery of recombinant proteins or
peptides may have therapeutic utility (see, for example, Waja-
peyee et al., 2008). It seems likely that these and other high-
throughput methods to functionally identify cancer genes will
produce further insights into the complexities of cancer develop-
ment and point toward new therapeutic targets.
EXPERIMENTAL PROCEDURES
Short Hairpin RNA Vectors
A miR-30-based shRNA library targeting the cancer 1000 gene set (2300
shRNAs) was subcloned into LMP and LMS (MSCV-based vectors) (Dickins
et al., 2005) in pools of 96 or 48 shRNAs, respectively. Individual shRNAs for
validation were synthesized as 97 bp oligos (Sigma Genosys), PCR-amplified,
cloned into LMS and LMP, and verified by sequencing. Targeting sequences
were selected on the basis of RNAi Codex (Silva et al., 2005) or BIOPREDsi
algorithms (Huesken et al., 2005) and are available upon request.
shRNA Recovery, Identification, and Determination
of Representation
Genomic DNA was isolated from tumor tissues (Puregene, Gentra Systems)
and the integrated proviral sequences were amplified with primers flanking
the miR30 cassette. The PCR product was digested with EcoRI/XhoI and
directionally cloned into LMS; 30–100 bacterial colonies were sequenced by
standard capillary sequencing for each tumor. For identifying the shRNAs
and determine their distribution, the sequence reads were aligned to a list of
all shRNAs used in the screen using the blat algorithm (Kent, 2002).
Stem Cell Isolation and Adoptive Transfer
All mouse experiments were performed in accordance with institutional and
national guidelines and regulations andwere approved by the InstitutionAnimal
Care and Use Committee (IACUC#06-02-97-17). Pregnant Em-Myc (C57BL/6)
mice were sacrificed to obtain embryonic 12.5–13.5 (E12.5–E13.5) fetal livers.
For hematopoietic reconstitution experiments, 6- to 8-week-old C57BL/6J
recipient mice received a single 7 Gy dose of total-body g-irradiation
(137Cesium source), and were reconstituted 24 hr later with approximately
3 3 106 viable fetal liver cells by tail vein injection. Flow cytometry analysis
was performed on a Becton Dickinson LSRII cell analyzer with FACSVantage
DiVa software and the Guava EasyCyte System with CytoSoft software.Lymphoma Monitoring and Analysis
Reconstituted animals were monitored for illness by lymph node palpation,
overall morbidity, and, in some cases, whole-body fluorescence imaging
(Schmitt and Lowe, 2002). Overall survival was defined as the time from
stem cell reconstitution until the animal reached morbidity and was sacrificed.
Statistical analysis was performed with a one-way ANOVA (analysis of
variance) test using Graph Pad Prism version 3.0 (Graph Pad Software). Immu-
nohistochemistry was performed using anti-caspase 3 and anti-PCNA
antibodies. Tumor cell DNA content was determined by flow cytometry with
propidium iodide staining of ethanol-fixed cells.
For additional Experimental Procedures, refer to the Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include four figures, Supplemental Experimental Proce-
dures, and four tables and can be found with this article online at http://
www.cell.com/cancer-cell/supplemental/S1535-6108(09)00262-1.
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